GLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ GenesGLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ Genes
Guide8 min read2026-03-22

Retatrutide: The Triple-Receptor Research Compound

Retatrutide produces the strongest Phase 2 weight signal in current literature — a breakdown of the receptor architecture, dose-response data, and how researchers stage it.

Why Retatrutide Draws Disproportionate Research Attention

Across published GLP-class compounds, Retatrutide currently produces the highest single-agent weight effect in Phase 2 data — −28.7% at 48 weeks at the top dose. That number is not incremental over the dual-agonist class; it is a meaningful step up that has shifted research attention.

The compound is available as GLP-3 R 15mg Retatrutide for standard research protocols and in larger formats for extended study designs.

Triple-Receptor Architecture

Retatrutide engages three receptors simultaneously, each contributing a distinct pathway:

  • GLP-1R: Hypothalamic appetite suppression, glucose-dependent insulin secretion, gastric emptying delay
  • GIPR: Potentiates GLP-1R insulin signaling, reduces nausea axis overlap, modulates adipose signaling
  • GcgR: Hepatic glucose modulation and thermogenic energy expenditure — the axis not present in tirzepatide

The GcgR contribution is what structurally separates Retatrutide from the dual-agonist class. Phase 2 attributed roughly 6–8 percentage points of additional weight effect to the glucagon axis above tirzepatide's baseline.

Phase 2 Dose-Response Summary

Weekly DoseMean % Weight ChangeDuration
1mg−8.7%48 wks
4mg−17.3%48 wks
8mg−22.8%48 wks
12mg−24.2%48 wks
24mg−28.7%48 wks

The curve shows clear dose-dependence without obvious plateau within the studied range.

How Protocols Typically Stage Retatrutide

Researchers generally follow the trial titration rhythm: begin low, escalate every 4 weeks, and hold at the target dose for the remaining protocol window. Dose escalation is the primary lever for reducing GI tolerability issues during initiation.

Purchasing and Handling Notes

Research-grade Retatrutide should carry >98% HPLC purity certification with third-party test reports available. The lyophilized powder is stable at −20°C long-term; reconstituted solutions should be held at 2–8°C and used within 28 days.

To start a Retatrutide research protocol, browse GLP-3 R 15mg Retatrutide.